source
- Novartis expands molecular glue program as Medicare drug spending surges and biotech firms report new data and fundingNovartis announced it is deepening its investment in molecular glue technology, a platform that aims to target previously undruggable proteins. The move signals the company’s confidence in the appr…
- Kardigan targets $320 million IPO to fund three late-stage heart drugsKardigan, a biotech focused on cardiovascular therapies, announced plans for an initial public offering that aims to raise about $320 million. The proceeds are intended to support the development…